Pinnacle Advisory Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Pinnacle Advisory Group’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,850	Closed	-$240K	–	125
2015 Q2	$240K	Sell	3,850 -4,154	-52%	-$259K	0.02%	87
2015 Q1	$494K	Hold	8,004	–	–	0.04%	85
2014 Q4	$432K	Buy	8,004 +10	+0.1%	+$546	0.04%	91
2014 Q3	$423K	Hold	7,994	–	–	0.05%	72
2014 Q2	$414K	Hold	7,994	–	–	0.05%	79
2014 Q1	$374K	Sell	7,994 -9,398	-54%	-$444K	0.04%	73
2013 Q4	$717K	Buy	17,392 +8,756	+101%	+$365K	0.08%	41
2013 Q3	$332K	Sell	8,636 -250	-3%	-$9.45K	0.04%	71
2013 Q2	$313K	Buy	+8,886	New	+$300K	0.04%	60

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

Pinnacle Advisory Group's XPH Position: Q3 2015 in Review

Pinnacle Advisory Group sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2015, closing a stake of 3,850 shares — an estimated $240K sold.

Pinnacle Advisory Group first reported a position in XPH in Q2 2013 and held it in 9 quarters. The position peaked at $717K in Q4 2013. 77 funds tracked by Wall St. Rank hold XPH as of Q3 2015.

Pinnacle Advisory Group reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2015 after selling out during the quarter.
Pinnacle Advisory Group sold 3,850 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2015, an estimated $240K.
Pinnacle Advisory Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 9 quarters.
Pinnacle Advisory Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $717K in Q4 2013.
77 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2015.

Based on Pinnacle Advisory Group's 13F filing for Q3 2015, filed 6 Nov 2015.